Prof. Dr Sven Francque (University of Antwerp, Belgium) kindly spoke with us about the additional analysis of the phase 2b NATIVE trial investigating lanifibranor in patients with NASH.
His presentation entitled ‘Lanifibranor therapy improves markers of lipid metabolism, insulin resistance, liver injury and fibrosis in patients with NASH and F2 and F3 fibrosis stages: a subgroup analysis of the phase 2b NATIVE study’ was given at EASL ILC 2021, 23-26 June.
Questions
- What is the rationale for the use of lanifibranor therapy in patients with NASH? (0:10)
- Could you briefly describe the aims, design and patient population of the NATIVE trial? (1:03)
- What were the effects of lanifibranor therapy on histological endpoints, and how did findings in the F2/F3 population compare with those of the overall patient population? (1:51)
- What effect did lanifibranor have on markers of liver injury, inflammation and fibrosis? (2:27)
- What was the safety and tolerability profile of lanifibranor? (3:27)
Disclosures: Prof. Dr Sven Francque has served as a speaker for AbbVie, Allergan, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Genentech, Genfit, Gilead, Intercept Pharmaceuticals, Inventiva, Novartis, NGM Bio, NovoNordisk and Roche. He has also acted as a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Genentech, Genfit, Gilead, Intercept Pharmaceuticals, Inventiva, Novartis, NGM Bio, Novo Nordisk and Roche.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
